Prosoma Pitch Deck (2022): 14-Slide Series A Deck

Prosoma’s 14-slide deck is a highly structured presentation that addresses the high-stakes world of Digital Therapeutics (DTx). The company focuses on the psychological burden of cancer, citing that over 50% of patients suffer from mental health issues. The deck excels by moving beyond simple app features to highlight rigorous clinical validation—showing a 15-50% reduction in anxiety and depression—and a sophisticated understanding of European and US healthcare reimbursement. While the financial projections are aggressive, aiming for a jump from €100k to €89.9M in revenue over five years, the…

Key takeaways

• The deck leads with clinical efficacy, citing a 15-50% reduction in anxiety and depression among oncology patients on slide 2.
• Prosoma utilizes a multi-pronged business model involving direct prescriptions, pharma partnerships, and payer reimbursement as shown on slide 7.
• Market validation is supported by real-world evidence from 468 patients across the EU and US, boasting a 90% recommendation rate on slide 5.
• The company provides a detailed regulatory and sales roadmap for Germany, targeting over 100,000 paid patients by 2027 on slide 8.
• The US strategy is clearly delineated with a timeline for FDA 510(k) submission and a projected price point of €815 on slide 9.
• The team slide (slide 6) is exceptionally strong, featuring ten members including a former German Minister of Health and a WHO consultant.
• Financial transparency is high, with a full table of projected revenues, expenses, and EBITDA through 2027 provided on slide 12.
• The 'Ask' is explicitly stated as a €6M Series A to reach €45M ARR and finalize US/Poland reimbursement pathways on slide 12.

Frequently asked questions

What is Prosoma's primary product?

Prosoma’s flagship product is 'Living Well,' a CE and ISO-compliant digital therapeutic application. It is designed to provide behavioral and psychological support to oncology patients, specifically targeting the reduction of stress, anxiety, and depression through Cognitive Behavioral Therapy (CBT) and adverse effect monitoring.

How does Prosoma generate revenue?

The company employs a B2B2C model. Revenue is generated through three main channels: direct reimbursement from payers/insurers (like the DiGA system in Germany), license-based payments from pharmaceutical companies for monitoring data, and partnerships with healthcare providers who prescribe the tool to patients.

What clinical evidence does the deck provide?

The deck cites data from 468 patients in real-world settings and 120 participants in randomized controlled trials (RCTs). These studies demonstrated a 15-50% reduction in anxiety and depression levels at 6 and 12 weeks post-intervention, along with a 39% user retention rate after four weeks.

What is the company's strategy for the US market?

Prosoma plans to enter the US via the Prescription Digital Therapeutic (PDT) pathway. The roadmap includes obtaining FDA Breakthrough Designation, conducting a US-based pivotal RCT, and submitting a 510(k) application, with a target launch as a PDT by 2025.

Who are the key investors and advisors?

The Series A was co-led by YouNick Mint and Simpact VC. The advisory board is a standout feature, including Dr. Philipp Rösler (former German Minister of Health), Prof. Tit Albreht (WHO consultant), and Markus Sieger (CEO of Polpharma).

Prosoma pitch deck: the facts

Company

Prosoma

Year

2022

Stage

Series A

Slides

14

Sector

Healthcare

Prosoma pitch deck PDF

The full Prosoma deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Prosoma pitch deck was used for

This is Prosoma’s 14‑slide **Series A** pitch deck from 2022 for a regulated **digital therapeutics platform for oncology patients**, centered on its CE‑marked medical device app **Living Well**. The deck was used to raise a **$3.2M Series A round closed on Dec 23, 2022**, focused on commercialization and further product development of its digital oncology support offering. It presents Prosoma as a medtech/digital health company integrating clinical evidence, multi‑market reimbursement strategy and data‑driven value creation for patients, providers and pharma.

Business model: Digital therapeutics and software-as-a-medical-device (SaMD) platform delivering psychological, behavioral and treatment-support programs for oncology patients, monetized via reimbursement, licensing to providers/pharma, and data-driven services.

Round

Series A

Lead investor

YouNick Mint and Simpact Ventures (co‑led the $3.2M round).

Investors

YouNick Mint, Simpact Ventures, RST Ventures for Earth, Pomerangels, Private angel investors

Founded

2017

Founders

Andrzej Jończyk, Ema Kufel, Marek Ostrowski, Piotr Grudziński

Headquarters

Berlin, Germany (Prosoma GmbH, Kurfürstendamm 50, 10707 Berlin).

Industry

Healthcare / Digital Health / MedTech / Digital Therapeutics (Oncology).

Year: 2022 (round closed Dec 23, 2022).

Raised: $3.2M (Series A, reported as $3.2M for commercialization and product development).

Total funding: At least $3.2M raised by Dec 23, 2022 (Series A), with later disclosures indicating total funding approximately $9.87M by 2025.

Use of funds as presented: Commercialization and further product development of Prosoma’s portfolio of oncology digital therapeutics, including completing the FDA reimbursement path in the US and scaling sales in Germany.

What happened after the Prosoma deck

The 2022 Series A deck contributed to Prosoma closing a $3.2M Series A financing to commercialize and further develop its Living Well oncology digital therapeutics platform, subsequently followed by additional funding rounds and continued product and market expansion efforts in Europe and the US.

• By Dec 23, 2022 Prosoma closed a **$3.2M Series A round** to fund commercialization and product development.
• Founders publicly planned to use Series A funding to **complete the FDA reimbursement path in the US and scale sales in
• Subsequent disclosures indicate Prosoma later secured additional capital (including a sizeable seed/pre‑Series A round a

What the Prosoma deck got right

• Clear regulatory differentiation as a certified medical device. The solution slide and external materials position **Living Well** as a CE‑marked, Class I medical device aligned with MDR 2017/745, providing regulated psychological and behavioral support to cancer patients, which is a strong differentiator versus generic mental health apps.
• Multi‑stakeholder value proposition across patients, providers and pharma. The deck’s framing of the solution explicitly addresses **patients (quality of life, stress/anxiety reduction), providers (time savings, improved outcomes and data), and pharma (upsell revenues, treatment‑relevant data)**, showing a thoughtful multi‑stakeholder value proposition in oncology care.
• Compelling revenue-plus-data enterprise value narrative. Prosoma emphasizes that **enterprise value comes from both revenue and data**, aligning its digital therapeutics platform with a broader data asset strategy and giving investors a clear rationale for long‑term upside beyond near‑term licensing and reimbursement.
• Strong linkage between regulatory milestones and commercialization strategy. The Series A narrative is tightly linked to a **reimbursement roadmap and commercialization plan** (FDA reimbursement path, scaling in Germany), which connects regulatory strategy to actual market access and monetization.
• Platform framing across the full oncology behavioral treatment journey. The company presents its offering as a **portfolio of digital therapeutics software products** tailored to different stages of the cancer journey (symptoms and treatment support, psycho‑social and behavioral support), suggesting extensibility beyond a single app and enhancing platform credibility in the deck.
• Strong investor validation from specialized health and impact funds. The deck is backed by a fundraising history with **healthcare‑focused and impact investors** (YouNick Mint, Simpact Ventures, RST Ventures for Earth, Pomerangels and others) already committing capital, which reinforces investor confidence in the team and model by the time of the Series A.

What could have been stronger

• Limited quantification of revenue model and pricing on business model slide. The deck’s OCR text for the **business model** slide is conceptually rich (reimbursement, licensing, data value) but lacks clearly quantified revenue streams, pricing tiers or concrete examples (e.g., per‑patient reimbursement, per‑license fees for hospitals), which may make it harder for investors to model near‑term financial outcomes solely from the deck.
• Clinical evidence and regulatory pathway not crisply summarized in OCR-visible slides. While clinical and regulatory compliance (CE/MDR, therapeutic benefits) are emphasized in external materials and referenced in the solution slide, the OCR text does not show a succinct **clinical evidence slide** with trial design, endpoints and results, potentially leaving questions about strength of evidence and regulatory classification at the time of the Series A pitch.
• Pharma revenue story mentioned but underdeveloped in visible content. The solution slide references value for **pharma (upselling revenues, data for better treatment)** but there is no clearly articulated pharma go‑to‑market, partnership pipeline or examples in the OCR‑visible content, which could weaken the credibility of pharma as a near‑term revenue driver in this deck.
• Data governance and privacy framework not explicit in the deck text we see. The OCR suggests references to data and monitoring, but there is no clear **data governance, privacy or regulatory slide** visible, leaving investor questions around HIPAA/GDPR, data ownership and monetization guardrails to be answered verbally rather than directly in the deck.

How an investor would read this deck

What draws attention

• Evidence that **Living Well** is a CE‑marked, Class I medical device aligned with MDR 2017/745, demonstrating Prosoma’s ability to navigate complex medical device regulation in oncology digital therapeutics.
• The **multi‑stakeholder value proposition** articulated in the solution slide: improved quality of life and reduced stress/anxiety for patients, time savings and better outcomes/data for providers, and upsell and data‑driven services for pharma.
• Prosoma’s positioning as a **portfolio of digital therapeutics** covering the behavioral needs of cancer patients across the journey, suggesting potential for product expansion beyond a single app.
• The **data asset narrative**, where enterprise value comes from both recurring revenues and longitudinal clinical/behavioral datasets generated by the platform.
• Founding team with a mix of clinical, psycho‑oncology and technology backgrounds, plus early traction with multiple investors across pre‑seed, seed and Series A rounds.

Risks that stand out

• Execution risk in achieving **reimbursement and commercialization** across multiple markets (Germany, US, broader EU), where timelines and policy changes can significantly affect revenue realization.
• Dependence on **clinical validation and regulatory status**: if future studies fail to replicate early results or regulators change digital therapeutics guidance, product positioning or pricing could be impacted.
• Competitive risk from other oncology‑focused digital health and mental health platforms, which may seek similar reimbursement pathways and partnerships, potentially commoditizing psychological support apps.
• Data privacy and regulatory risk related to handling sensitive oncology and mental health data across jurisdictions (EU MDR, GDPR, HIPAA), especially if the data monetization strategy is central to enterprise value.
• Pharma‑oriented revenue is not yet fully articulated; if pharma partnerships or upsell revenues materialize slower than expected, the data‑driven enterprise value thesis could be delayed and Series A funds may primarily support provider/patient channels rather than diversified revenue streams.

Questions this deck invites

• What concrete **clinical studies** underpin Living Well (study design, sample size, endpoints, comparator, observed effect sizes on anxiety/depression/stress, and publication status)?
• How does Prosoma’s **reimbursement model** work country by country (Germany, Poland, other EU markets, and the US), including current reimbursement codes, pricing per patient, and realized vs. projected coverage?
• What are Prosoma’s current **commercial traction metrics** (active users, contracted providers, churn, average revenue per user/provider, and pipeline of pharma/hospital contracts) since the 2022 Series A?
• How is **data handled and monetized** (data ownership, consent, anonymization, regulatory compliance such as GDPR/HIPAA, and whether data is sold, licensed, or used only for internal analytics)?
• How crowded is the **competitive landscape in oncology digital therapeutics and mental health support**, and what defensible differentiation (clinical outcomes, regulatory approvals, integration, AI personalization) does Prosoma demonstrate

What founders can take from the Prosoma deck

• A regulated digital therapeutics company can use its pitch deck to **make regulatory compliance a core part of the value proposition**, explicitly calling out CE marking, MDR alignment and ISO‑based processes to reassure investors about risk in a tightly regulated space.
• For multi‑stakeholder healthcare products, clearly mapping **value for patients, providers and pharma** on a single solution slide helps investors see how one platform can support several revenue channels and strategic outcomes.
• Even at Series A, articulating that **enterprise value comes from both revenue and data** can frame the company as a long‑term digital health data asset rather than a single app, which is attractive for investors focused on platform plays.
• Showing a **reimbursement and commercialization roadmap across geographies** (e.g., US FDA reimbursement path and scaling sales in Germany) connects regulatory milestones to concrete market entry plans, increasing confidence that clinical evidence will translate into actual revenue.
• Prosoma’s fundraising trajectory (pre‑seed, seed, Series A with multiple specialized healthcare and impact investors) illustrates how **impact‑oriented and health‑tech funds can be sequenced** to support a digital therapeutics company through validation, certification and early commercialization.
• Positioning the product as a **portfolio of digital therapeutics tailored to stages of the cancer journey** rather than a generic wellness app helps differentiate it within crowded digital mental health markets and justify medical device classification.

Prosoma pitch deck: common questions

What does Prosoma do?

Prosoma is a medtech/digital health company developing **digital therapeutics and software-as-a-medical-device** products for oncology patients, with a flagship CE‑marked Class I medical device app called **Living Well** that provides psychological, behavioral and treatment support to cancer patients, survivors and caregivers.

How much did Prosoma raise with this Series A pitch deck, and who invested?

Prosoma’s 2022 Series A deck was used for a **$3.2M Series A round closed on Dec 23, 2022**, aimed at commercialization and further development of its digital oncology therapeutics platform; the round was co‑led by **YouNick Mint** and **Simpact Ventures**, with participation from **RST Ventures for Earth**, **Pomerangels** and angels.

Is Prosoma’s Living Well product a certified medical device?

Prosoma’s flagship product **Living Well** is a **CE‑marked Class I medical device** aligned with the European Medical Device Regulation 2017/745 (MDR) and compliant with medical device CE marking requirements; it is designed to improve quality of life and reduce stress, anxiety and depression related to cancer diagnosis and treatment.

Who founded Prosoma and when?

Prosoma was launched in **2017** by **Andrzej Jończyk, Ema Kufel, Marek Ostrowski and Piotr Grudziński** as a company focused on digital therapeutics software for cancer patients, offering symptom and treatment support, psycho‑social and behavioral support across the cancer journey.

What were Prosoma’s main goals for the funding raised with this deck?

According to the 2022 reporting, Prosoma’s Series A round of **$3.2M** was primarily intended to fund **commercialization, multi‑market reimbursement efforts, completion of the FDA reimbursement path in the US, and scaling sales in Germany** for its oncology digital therapeutics platform.

Sources

Funding and outcome facts on this page were researched on 2026-08-21 from the pages below.

• Polish medtech startup Prosoma raises ＄3.2M - AIN
• Prosoma – Funding, Valuation, Investors, News
• Prosoma compliant with medical device CE marking
• Living Well - Prosoma
• Prosoma - homepage
• ENG_White_Paper_Living Well
• Marek Ostrowski | Frontiers Health
• Aleksander Kłósek's Post

Prosoma pitch deck slides

What each slide of the Prosoma pitch deck says

Slide 1

prosoma 0 IEEE ’ pr [ TAL THERAPEUT 5 4 pe) ° a Pp “This Company Is On A Mission | To Become A Global Leader Bh 2°% In Digital Therapeutics JF Va eo For Oncology™* o® ¥.oco € Emanuela Kufel -

Slide 2

s prosoma ( ) ry Living Well O ' N We developed a evidence based digital == £4 um Na It is already prescribed by doctors in Germany therapeutics and adverse effects mm flo and by the end of 2024 will also be in the US monitoring application that is CE it NE n and Poland. and ISO compliant. s oui 9 A Our goal is to reach 250k patients per year I efectvly reduces level of aniety, pry ey and to build largest data-driven solution ress an of Oncology Pig? for Oncology. Where are we? ak Scaling sales Dot peiopment CEcontcation | OTA PAS pmbmamers mCamary FOAL Scales ) . h Germany © ® 2021-2022 (SM EUR) ® 2023 -2025 (6M EUR - open) Graduate from business 3 UGS & als, accelerators ERE

Slide 3

prosoma B) Problem Eat Healthcare systems around the world fail to deliver sufficient behavioural and psychological support for cancer patients. There is 18 million cancer diagnosis per year worldwide - More than 50% of those patients suffer with mental health problems. Healthcare systems & Cancer patients are not equipped to deliver -/) lack behavioural and comprehensive care. 0) psychological support* + Behavioural support is incredibly labour + 147% more likely to require emergency intensive. > care. + There is a significant shortage of required + 75% more likely to be re-hospitalised skilled personnel. in 30 days. + There are financial, geographical and + 113% higher cost of care for ca…

Slide 4

Solution Living Well O CE/150 compliant Medical Devico available for prescription and on license-base. Cover needs of: Patient improves quality of ife and treatment management. reduces stress and arety. Provider saves time, improves. outcomes, gathers data. prosoma cominginzos g} monitoring et engaging and joyul Gighal therapeutics Pharma @' upseling revenues. comprehensive services, Gata fo better trestment.

Slide 5

Sco prosoma @) The Validation ET Living Well is validated both in clinical trials and real world settings 7 © Real World Evidence Clinical Trials 0 = Data gathered from 468 cancer patients from 120 participant in randomised controlled trials the EU and the US shows: showed lowered anxiety and depression levels by 15%-50% 6 and 12 weeks after the intervention. AN . % NG p— i 1 39% 90% Som rm by A = / 50-60% lower user retention after would —— Control Group Livin Well group levels of stress 4 weeks (S-10times recommend and anxiety better than other to a friend 3 ongoing RCTs leading medical apps) ran by cancer centers in Germany, USA, and Poland - final results in Q2 23 5

Slide 6

t dvi T prosoma Oo z GlosAL 8% Microsoft ow Marek Ostrowski Andrzej Joficzyk, M.D. Ema Kufel Piotr Grudzinski Prof. Ewa Wojtyna Se hie mdm coir pro faslcayinl Pyssicpid pisgutaba russ: Colt ett crncer rine ne. SE ee 9) |= [Eup] wr polpharma © asxeepos Wojciech Szczepaniak Dr Philipp Résler Prof Tit Albreht Markus Sieger dr Georgia Schilling strategic management. graduate [— 6

Slide 7

Business model Product reimbursement and clinical data. ICENSE. PAYMENT = affocts and treatment monitoring Data prosoma () - L ocon - N Enterprise Value comes from revenue and Data

Slide text above is read directly from the Prosoma deck PDF embedded on this page.

Related fundraising guides (24)

• How to Calculate Your Fundraising Ask and Justify It to Investors
• How to Present Financial Projections to Investors
• How to Use Video in Your Pitch Deck: The Definitive Guide
• Buffer Pitch Deck Breakdown: Lessons from a $450K Seed Round
• The Three Pitch Decks You Need to Raise a Seed Round
• How to Design a Pitch Deck Cover That Gets Your Deck Opened
• The Tactical Guide to Pitch Deck Color Psychology
• How to Read Investor Body Language During Your Startup Pitch
• The Best Font For Your Pitch Deck: A Founder's Guide
• The 12-Slide Pitch Deck Investors Actually Want to See
• How to Write a Pitch Deck Tagline That Gets Investors to Slide 2
• Your Pitch Deck Is Too Long. Here’s How to Fix It.
• Brex Pitch Deck Breakdown
• How to Create a Financial Slide With No Revenue
• How to Frame Your Business Model in a Pitch Deck
• How Investors Actually Review Pitch Decks
• Intercom Pitch Deck Breakdown: How to Sell a Category-Defining Vision
• How to Create a Pitch Deck That Actually Gets Funded
• How to Show Growth in a Pitch Deck
• How to Create a Pitch Deck That Actually Stands Out
• MySQL 2003 Series B Pitch Deck Breakdown
• How to Create a Pitch Deck That Gets Funded
• How to Create Fundraising Materials That Actually Close Investors
• The Hard Truth About Pitch Decks: An Actionable Guide for Founders

This deck's categories (2)

• Healthtech & Biotech Pitch Deck Examples
• Series A & Series B Pitch Deck Examples

Decks from the same year (1)

• 2022 pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $1M to $10M

Browse companies alphabetically (1)

• Pitch decks from companies starting with P

Decks in the same category (12)

• Oscar Health Pitch Deck Breakdown
• AKO Smart Technologies Pitch Deck Breakdown: Real Trial Data, and a Budget That Contradicts It
• Slope Pitch Deck Breakdown: Solving the Clinical Trial Supply Chain Crisis
• Sollis Health Pitch Deck Breakdown: Selling High-Acuity Concierge Medicine
• MedArrive Pitch Deck Breakdown: Leveraging EMS Networks for In-Home Care Delivery
• Twin Health Pitch Deck Breakdown: A Clinical Masterclass in Series C Storytelling
• AccuRx Pitch Deck Breakdown: Dominating NHS Communication with a 96% Market Share
• Akido Labs Pitch Deck Breakdown: Solving Healthcare Data Silos with a Human-Centric Narrative
• Aurion Biotech Pitch Deck Breakdown: Scaling Cell Therapy for Global Blindness
• Kensho Health Pitch Deck Breakdown: A $3.5M Seed Round Built on Provider Supply and Evidence
• WellTrack Pitch Deck Breakdown: A 7-Slide Masterclass in Minimalist Traction
• Whylab Pitch Deck Breakdown: Selling the Digital Gym for Mental Fitness

More pitch deck teardowns (16)

• Propel IP Pitch Deck Teardown: Modernizing the Fishing Tournament Economy
• Properati Pitch Deck Teardown: A Performance-Based Play for LatAm Real Estate
• Properati Pitch Deck Breakdown: A Performance-Based Pivot for LatAm Real Estate
• Proper Finance Pitch Deck Teardown: A Minimalist Approach to Fintech Infrastructure
• Proper Pitch Deck Breakdown: A $9.5M Seed Round for Holistic Sleep Wellness
• PropMap Pitch Deck Teardown: A Highly Theoretical Approach to Crowdsourced Knowledge Mapping
• ProSky Pitch Deck Breakdown: A Minimalist 8-Slide Traction-First Approach
• ProSmart (Sportgo) Pitch Deck Teardown: A Public Company's Play for the Global Sports Market
• TexasCashFlow.com Pitch Deck Teardown: A Case Study in Hyper-Local Real Estate Arbitrage
• Protecto Pitch Deck Breakdown: Securing the Generative AI Data Lifecycle
• Protrainy Pitch Deck Teardown: A Niche EdTech Play for the Indian Construction Sector
• Pro Vdn Pitch Deck Teardown: A B2B Video Infrastructure Play for the Early Streaming Era
• Pruna AI Pitch Deck Breakdown: Selling Efficiency in the Generative AI Gold Rush
• Prynt Pitch Deck Breakdown: A Hardware-as-a-Trojan-Horse Strategy for Augmented Reality
• Public Goods Pitch Deck Breakdown: A Masterclass in Visual Storytelling and Supply Chain Logic
• Altum Pitch Deck Teardown: A State-Backed Debt Issuance for Economic Development

Recently published pitch deck teardowns (12)

• Knuffle Bunny and Friends Pitch Deck Teardown: A Creative Pitch for Animated IP Expansion
• Koi Gardens Energy Ranch Pitch Deck Teardown: A Geothermal Aquaculture Play
• Knowhere Pitch Deck Teardown: A Visual-First Travel Discovery Concept
• Kredivo Pitch Deck Teardown: A $2.5 Billion SPAC Transaction Analysis
• Kyra Pitch Deck Teardown: Transitioning from a Creative Agency to a $10M Series A SaaS Platform
• LABELit.cc Pitch Deck Teardown: A Crowdsourced Affiliate Model for Visual Commerce
• Lantern Pharma Pitch Deck Teardown: Scaling AI-Driven Oncology Through Data and Trials
• Lara Exploration Pitch Deck Teardown: The Prospect Generator Model in Mining
• Le Camping Pitch Deck Teardown: A Zero-Equity Accelerator Model for the French Ecosystem
• Lbi Pitch Deck Teardown: A Multi-Vertical Investment Vehicle Targeting the Nigerian Market
• Legacy Education Alliance Pitch Deck Teardown: Monetizing Financial Literacy Brands
• LENS UNO Pitch Deck Teardown: A Marketplace Framework Lacking Hard Traction Data

Browse by topic (1)

• Pitch Deck guides

Fundraising library · Pitch deck examples · Investor directory · Founder database